Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3

Sponsor
AB Science
Study ID
NCT00866138
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This phase 2 study was designed to assess the safety and efficacy of masitinib (AB1010) in patients with relapsing/refractory t(4;14) Multiple Myeloma. Response and progression were assessed according to the Bladé revised IMWG criteria1 from lowest point.

Key Dates

Start date
Feb 28, 2005
Status verified
Dec 2019
Primary completion
Jan 31, 2011
Completion
Jan 31, 2011

Study Design

Enrollment
24 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1
    masitinib (AB1010)

Primary Outcome Measure

Tumor Response Rate, based on the criteria published by Blade and on the criteria SWOG [ Time Frame: 16 weeks ]

Related Studies